Iovance picks up IL-2 Proleukin for $200M+ upfront; Estrella Biopharma to wait for SPAC deal finish
The UK-based biotech Clinigen will divest from one of its IL-2 candidates and sell it to Iovance Biotherapeutics.
In an announcement on Monday, Iovance will pay £166.7 ($205.9 million) to Clinigen for Proleukin, a cytokine that can be used in treating metastatic renal cell carcinoma and metastatic melanoma but has been investigated for other uses as well. The agreement will also see a £41.7 million ($51.4 million) milestone payment upon the “first approval” of lifileucel for advanced melanoma. The deal is expected to close in the first quarter of 2023.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
